Anti-Angiogenic Treatment of Gastrointestinal Malignancies

REFERENCES

• Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 1971; 285(21)1182–1186, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3)353–364, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Tonini T., Rossi F., Claudio P. P. Molecular basis of angiogenesis and cancer. Oncogene 2003; 22(42)6549–6556, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Abdulrauf S. I., Edvardsen K., Ho K. L., Yang X. Y., Rock J. P., Rosenblum M. L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low–grade astrocytoma. J. Neurosurg. 1998; 88(3)513–520, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Cascinu S., Staccioli M. P., Gasparini G., Giordani P., Catalano V., Ghiselli R., Rossi C., Baldelli A. M., Graziano F., Saba V., Muretto P., Catalano G. Expression of vascular endothelial growth factor can predict event–free survival in stage II colon cancer. Clin. Cancer Res. 2000; 6(7)2803–2807, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Inoue K., Slaton J. W., Karashima T., Yoshikawa C., Shuin T., Sweeney P., Millikan R., Dinney C. P. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin. Cancer Res. 2000; 6(12)4866–4873, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mineta H., Miura K., Ogino T., Takebayashi S., Misawa K., Ueda Y., Suzuki I., Dictor M., Borg A., Wennerberg J. Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas. Br. J. Cancer 2000; 83(6)775–781, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shen G. H., Ghazizadeh M., Kawanami O., Shimizu H., Jin E., Araki T., Sugisaki Y. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br. J. Cancer 2000; 83(2)196–203, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Shih C. H., Ozawa S., Ando N., Ueda M., Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 2000; 6(3)1161–1168, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Slaton J. W., Inoue K., Perrotte P., El-Naggar A. K., Swanson D. A., Fidler I. J., Dinney C. P. Expression levels of genes that regulate metastasis and angiogenesis correlate with advanced pathological stage of renal cell carcinoma. Am. J. Pathol. 2001; 158(2)735–743, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Yudoh K., Kanamori M., Ohmori K., Yasuda T., Aoki M., Kimura T. Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br. J. Cancer 2001; 84(12)1610–1615, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2004; 350(23)2335–2342, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gimbrone M. A., Jr., Leapman S. B., Cotran R. S., Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J. Exp. Med. 1972; 136(2)261–276, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Pugh C. W., Ratcliffe P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat. Med. 2003; 9(6)677–684, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Demicheli R., Abbattista A., Miceli R., Valagussa P., Bonadonna G. Time distribution of the recurrence risk for breast cancer patients undergoing mastectomy: further support about the concept of tumor dormancy. Breast Cancer Res. Treat. 1996; 41(2)177–185, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Demicheli R., Terenziani M., Valagussa P., Moliterni A., Zambetti M., Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J. Natl. Cancer Inst. 1994; 86(1)45–48, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Dvorak H. F. Rous-Whipple Award Lecture How tumors make bad blood vessels and stroma. Am. J. Pathol. 2003; 162(6)1747–1757, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• McCarty M. F., Liu W., Fan F., Parikh A., Reimuth N., Stoeltzing O., Ellis L. M. Promises and pitfalls of anti-angiogenic therapy in clinical trials. Trends. Mol. Med. 2003; 9(2)53–58, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cross M. J., Dixelius J., Matsumoto T., Claesson-Welsh, VEGF-receptor L. signal transduction. Trends. Biochem. Sci. 2003; 28(9)488–494, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Karkkainen M. J., Petrova T. V. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 2000; 19(49)5598–5605, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dvorak H. F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol. 2002; 20(21)4368–4380, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petit A. M., Rak J., Hung M. C., Rockwell P., Goldstein N., Fendly B., Kerbel R. S. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol. 1997; 151(6)1523–1530, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gately S., Li W. W. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol. 2004; 31: 2–11, 2 Suppl 7[PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hubbard S. R. Structural analysis of receptor tyrosine kinases. Prog Biophys Mol. Biol. 1999; 71(3–4)343–358, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Senger D. R., Van de Water L., Brown L. F., Nagy J. A., Yeo K. T., Yeo T. K., Berse B., Jackman R. W., Dvorak A. M., Dvorak H. F. Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev. 1993; 12(3–4)303–324, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Murohara T., Horowitz J. R., Silver M., Tsurumi Y., Chen D., Sullivan A., Isner J. M. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998; 97(1)99–107, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tsurumi Y., Murohara T., Krasinski K., Chen D., Witzenbichler B., Kearney M., Couffinhal T., Isner J. M. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat. Med. 1997; 3(8)879–886, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• van der Zee R., Murohara T., Luo Z., Zollmann F., Passeri J., Lekutat C., Isner J. M. Vascular endothelial growth factor/vascular permeability factor augments nitric oxide release from quiescent rabbit and human vascular endothelium. Circulation 1997; 95(4)1030–1037, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wheeler-Jones C., Abu-Ghazaleh R., Cospedal R., Houliston R. A., Martin J., Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997; 420(1)28–32, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat. Rev. Cancer. 2002; 2(11)826–835, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Partanen T. A., Alitalo K., Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86(11)2406–2412, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Valtola R., Salven P., Heikkila P., Taipale J., Joensuu H., Rehn M., Pihlajaniemi T., Weich H., de Waal R., Alitalo K. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am. J. Pathol. 1999; 154(5)1381–1390, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Makinen T., Olofsson B., Karpanen T., Hellman U., Soker S., Klagsbrun M., Eriksson U., Alitalo K. Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1. J. Biol. Chem. 1999; 274(30)21217–21222, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Murga M., Fernandez-Capetillo O., Tosato G. Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. Blood 2005; 105(5)1992–1999, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Eskens F. A. Angiogenesis inhibitors in clinical development; where are we now and where are we going?. Br. J. Cancer 2004; 90(1)1–7, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Siemann D. W., Chaplin D. J., Horsman M. R. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004; 100(12)2491–2499, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Kitadai Y., Bucana C. D., Cleary K. R., Ellis L. M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995; 55(18)3964–3968, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Takahashi Y., Tucker S. L., Kitadai Y., Koura A. N., Bucana C. D., Cleary K. R., Ellis L. M. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch. Surg. 1997; 132(5)541–546, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tokunaga T., Oshika Y., Abe Y., Ozeki Y., Sadahiro S., Kijima H., Tsuchida T., Yamazaki H., Ueyama Y., Tamaoki N., Nakamura M. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br. J. Cancer 1998; 77(6)998–1002, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Presta L. G., Chen H., O'Connor S. J., Chisholm V., Meng Y. G., Krummen L., Winkler M., Ferrara N. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997; 57(20)4593–4599, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Gordon M. S., Margolin K., Talpaz M., Sledge G. W., Jr., Holmgren E., Benjamin R., Stalter S., Shak S., Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 2001; 19(3)843–850, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Margolin K., Gordon M. S., Holmgren E., Gaudreault J., Novotny W., Fyfe G., Adelman D., Stalter S., Breed J. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J. Clin. Oncol. 2001; 19(3)851–856, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kabbinavar F., Hurwitz H. I., Fehrenbacher L., Meropol N. J., Novotny W. F., Lieberman G., Griffing S., Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol. 2003; 21(1)60–65, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Petrelli N., Douglass H. O., Jr., Herrera L., Russell D., Stablein D. M., Bruckner H. W., Mayer R. J., Schinella R., Green M. D., Muggia F. M. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J. Clin. Oncol. 1989; 7(10)1419–1426, [CSA]
   Google Scholar
• Hurwitz H. I., Fehrenbacher L., Hainsworth J. D., Heim W., Berlin J., Holmgren E., Hambleton J., Novotny W. F., Kabbinavar F. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 2005; 23(15)3502–3508, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kabbinavar F. F., Schulz J., McCleod M., Patel T., Hamm J. T., Hecht J. R., Mass R., Perrou B., Nelson B., Novotny W. F. Addition of Bevacizumab to Bolus Fluorouracil and Leucovorin in First-Line Metastatic Colorectal Cancer: Results of a Randomized Phase II Trial. J. Clin. Oncol. 2005; 23(16)3697–3705, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kabbinavar F. F., Hambleton J., Mass R. D., Hurwitz H. I., Bergsland E., Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol. 2005; 23(16)3706–3712, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giantonio B. J., Catalano P. J., Meropol N. J., O'Dwyer P. J., Mitchell E. P., Alberts S. R., Schwartz M. A., Benson A. B. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. Proc. Am. Soc. Clin. Oncol, Clin J. Oncol. 2005, Abs 2[CSA]
   Google Scholar
• Chen H. X., Mooney M., Boron M., Grochow L., Zwiebel J., Vena D., Mosby K., Grandinetti C., Kaplan R. S. Bevacizumab (BV) plus 5-FU/leucovorin (FU/LV) for advanced colorectal cancer (CRC) that progressed after standard chemotherapies: An NCI Treatment Referral Center trial (TRC-0301). Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S), Abs. 3515[CSA]
   Google Scholar
• Saltz L. B., Lenz H., Hochster H., Wadler S., Hoff P., Kemeny N., Hollywood E., Gonen M., Wetherbee S., Chen H. Randomized Phase II Trial of Cetuximab/Bevacizumab/Irinotecan (CBI) versus Cetuximab/Bevacizumab (CB) in Irinotecan-Refractory Colorectal Cancer. Orlando, FL 2005, in Proc. Am. Soc. Clin. Oncol.
   Google Scholar
• Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 2004; 351(4)337–345, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Giantonio B. J., Chen H. X., Catalano P. J., Meropol N. J., O'Dwyer P. J., Benson A. B. Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200. Proc. Am. Soc. Clin. Oncol., J. Clin. Oncol. 2004; 22(14S), Abs. 3017[CSA]
   Google Scholar
• Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J., Kabbinavar F., Novotny W., Scappaticci F. Wound healing/bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S), Abs. 3702[CSA]
   Google Scholar
• Scappaticci F., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J., Griffing S., Holmgren E., Kabbinavar F., Novotny W., Hurwitz H. Analysis of wound healing and bleeding post-surgery in metastatic colorectal cancer patients treated with bevacizumab, in Gastrointestinal Cancers Symposium. Am. Soc. Clin. Oncol. 2004, [CSA]
   Google Scholar
• Scappaticci F., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J., Kabbinavar F., Novotny W., Hurwitz H. Lack of effect of bevacizumab on wound healing/bleeding complications when given 28–60 days following primary cancer surgery. Proc. Am. Soc. Clin. Oncol., of J. Clin. Oncol. 2004; 22(14S), Abs. 3530[CSA]
   Google Scholar
• Hambleton J., Novotny W. F., Hurwitz H., Fehrenbacher L., Cartwright T., Hainsworth J., Heim W., Berlin J., Kabbinavar F., Holmgren E. Bevacizumab does not increase bleeding in patients with metastatic colorectal cancer receiving concurrent anticoagulation. Proc. Am. Soc. Clin. Oncol. J. Clin. Oncol. 2004; 22: 14S, Abs. 3528[CSA]
   Google Scholar
• Barron H. Important Drug Warning. August, 122004. Genentech, Inc, Available online http://www.fda.gov/medwatch/SAFETY/2004/avastin_deardoc_mod.pdf. Food and Drug Administration, accessed 2004
   Google Scholar
• Jain R. K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat. Med. 2001; 7(9)987–989, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Willett C. G., Boucher Y., di Tomaso E., Duda D. G., Munn L. L., Tong R. T., Chung D. C., Sahani D. V., Kalva S. P., Kozin S. V., Mino M., Cohen K. S., Scadden D. T., Hartford A. C., Fischman A. J., Clark J. W., Ryan D. P., Zhu A. X., Blaszkowsky L. S., Chen H. X., Shellito P. C., Lauwers G. Y., Jain R. K. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004; 10(2)145–147, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Holash J., Davis S., Papadopoulos N., Croll S. D., Ho L., Russell M., Boland P., Leidich R., Hylton D., Burova E., Ioffe E., Huang T., Radziejewski C., Bailey K., Fandl J. P., Daly T., Wiegand S. J., Yancopoulos G. D., Rudge J. S. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. U. S. A. 2002; 99(17)11393–11398, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kim E. S., Serur A., Huang J., Manley C. A., McCrudden K. W., Frischer J. S., Soffer S. Z., Ring L., New T., Zabski S., Rudge J. S., Holash J., Yancopoulos G. D., Kandel J. J., Yamashiro D. J. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc. Natl. Acad. Sci. U. S. A. 2002; 99(17)11399–11404, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Byrne A. T., Ross L., Holash J., Nakanishi M., Hu L., Hofmann J. I., Yancopoulos G. D., Jaffe R. B. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin. Cancer Res. 2003; 9(15)5721–5728, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Frischer J. S., Huang J., Serur A., Kadenhe-Chiweshe A., McCrudden K. W., O'toole K., Holash J., Yancopoulos G. D., Yamashiro D. J., Kandel J. J. Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. Int. J. Oncol. 2004; 25(3)549–553, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fukasawa M., Korc M. Vascular endothelial growth factor-trap suppresses tumorigenicity of multiple pancreatic cancer cell lines. Clin Cancer Res. 2004; 10(10)3327–3332, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Huang J., Frischer J. S., Serur A., Kadenhe A., Yokoi A., McCrudden K. W., New T., O'Toole K., Zabski S., Rudge J. S., Holash J., Yancopoulos G. D., Yamashiro D. J., Kandel J. J. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc. Natl. Acad. Sci. U. S. A. 2003; 100(13)7785–7790, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dupont J., Camastra D., Gordon M. S., Mendelson D., Murren J., Hsu A., Lucarelli A., Cedarbaum J. M., Spriggs D. R. Phase 1 study of VEGF Trap in patients with solid tumors and lymphoma. Proc. Am. Soc. Clin. Oncol. 2003; 22, Abs. 776[CSA]
   Google Scholar
• Dupont J., Schwartz L., Koutcher J., Spriggs D., Gordon M., Mendelson D., Murren J., Lucarelli A., Cedarbaum J. Phase I and pharmacokinetic study of VEGF Trap administered subcutaneously (sc) to patients (pts) with advanced solid malignancies. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S)3009, [CSA]
   Google Scholar
• Prewett M., Huber J., Li Y., Santiago A., O'Connor W., King K., Overholser J., Hooper A., Pytowski B., Witte L., Bohlen P., Hicklin D. J. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 1999; 59(20)5209–5218, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bruns C. J., Liu W., Davis D. W., Shaheen R. M., McConkey D. J., Wilson M. R., Bucana C. D., Hicklin D. J., Ellis L. M. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000; 89(3)488–499, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Posey J. A., Ng T. C., Yang B., Khazaeli M. B., Carpenter M. D., Fox F., Needle M., Waksal H., LoBuglio A. F. A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin. Cancer Res. 2003; 9(4)1323–1332, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Laird A. D., Christensen J. G., Li G., Carver J., Smith K., Xin X., Moss K. G., Louie S. G., Mendel D. B., Cherrington J. M. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. Faseb. J. 2002; 16(7)681–690, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Abrams T. J., Lee L. B., Murray L. J., Pryer N. K., Cherrington J. M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol. Cancer. Ther. 2003; 2(5)471–478, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Abrams T. J., Murray L. J., Pesenti E., Holway V. W., Colombo T., Lee L. B., Cherrington J. M., Pryer N. K. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer. Mol. Cancer Ther. 2003; 2(10)1011–1021, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mendel D. B., Laird A. D., Xin X., Louie S. G., Christensen J. G., Li G., Schreck R. E., Abrams T. J., Ngai T. J., Lee L. B., Murray L. J., Carver J., Chan E., Moss K. G., Haznedar J. O., Sukbuntherng J., Blake R. A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J. M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet–derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer. Res. 2003; 9(1)327–337, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• O'Farrell A. M., Abrams T. J., Yuen H. A., Ngai T. J., Louie S. G., Yee K. W., Wong L. M., Hong W., Lee L. B., Town A., Smolich B. D., Manning W. C., Murray L. J., Heinrich M. C., Cherrington J. M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101(9)3597–3605, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Raymond E., Faivre S., Vera K., Delbaldo C., Robert C., Spatz A., Bello C., Brega N., Scigalla P., Armand J. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc. Am. Soc. Clin. Oncol. 2003, Abs. 769[CSA]
   PubMedGoogle Scholar
• Rosen L., Mulay M., Long J., Wittner J., Brown J., Martino A. -M., Bello C. L., Walter S., Scigalla P., Zhu J. Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2003, Abs. 765[CSA]
   Web of Science ®Google Scholar
• Thomas A. L., Morgan B., Drevs J., Unger C., Wiedenmann B., Vanhoefer U., Laurent D., Dugan M., Steward W. P. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584. Semin. Oncol. 2003; 30: 32–38, 3 Suppl 6[PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Wood J. M., Bold G., Buchdunger E., Cozens R., Ferrari S., Frei J., Hofmann F., Mestan J., Mett H., O'Reilly T., Persohn E., Rosel J., Schnell C., Stover D., Theuer A., Towbin H., Wenger F., Woods-Cook K., Menrad A., Siemeister G., Schirner M., Thierauch K. H., Schneider M. R., Drevs J., Martiny-Baron G., Totzke F. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. 2000; 60(8)2178–2189, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Morgan B., Thomas A. L., Drevs J., Hennig J., Buchert M., Jivan A., Horsfield M. A., Mross K., Ball H. A., Lee L., Mietlowski W., Fuxuis S., Unger C., O'byrne K., Henry A., Cherryman G. R., Laurent D., Dugan M., Marme D., Steward W. P. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J. Clin. Oncol. 2003; 21(21)3955–3964, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Schleucher N., Trarbach T., Junker U., Tewes M., Masson E., Lebwohl D., Seeber S., Laurent D., Vanhoefer U. Phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., J. Clin. Oncol. 2004; 22(14S)3558, [CSA]
   PubMedGoogle Scholar
• Steward W. P., Thomas A. L., Morgan B., Wiedenmann B., Bartel C., Vanhoefer U., Trarbach T., Junker U., Laurent D., Lebwohl D. Expanded phase I/II study of PTK787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in combination with FOLFOX-4 as first-line treatment for patients with metastatic colorectal cancer. Proc. Am. Soc. Clin. Oncol., J. Clin. Oncol. 2004; 22(14S)3556, [CSA]
   Google Scholar
• Hecht J. R., Trarbach T., Jaeger E., Hainsworth J., Wolff R., Lloyd K., Bodoky G., Borner M., Laurent D., Jacques C. A randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). in Proc. Am. Soc. Clin. Oncol., Orlando, FL 2005
   Google Scholar
• Wilhelm S. M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L. E., Bollag G., Trail P. A. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004; 64(19)7099–7109, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Heim M., Scharifi M., Zisowsky J., Jaehde U., Voliotis D., Seeber S., Strumberg D. The Raf kinase inhibitor BAY 43–9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines. Anticancer Drugs 2005; 16(2)129–136, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Strumberg D., Richly H., Hilger R. A., Schleucher N., Korfee S., Tewes M., Faghih M., Brendel E., Voliotis D., Haase C. G., Schwartz B., Awada A., Voigtmann R., Scheulen M. E., Seeber S. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43–9006 in patients with advanced refractory solid tumors. J. Clin. Oncol. 2005; 23(5)965–972, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Wedge S. R., Ogilvie D. J., Dukes M., Kendrew J., Chester R., Jackson J. A., Boffey S. J., Valentine P. J., Curwen J. O., Musgrove H. L., Graham G. A., Hughes G. D., Thomas A. P., Stokes E. S., Curry B., Richmond G. H., Wadsworth P. F., Bigley A. L., Hennequin L. F. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002; 62(16)4645–4655, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Hurwitz H., Holden S. N., Eckhardt S. G., Rosenthal M., de Boer R., Rischin D., Green M., Basser R. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2002, Abs. 325[CSA]
   Google Scholar
• Minami H., Ebi H., Tahara M., Sasaki Y., Yamamoto N., Yamada Y., Tamura T., Saijo N. A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 2003, Abs. 778[CSA]
   Google Scholar
• Beebe J. S., Jani J. P., Knauth E., Goodwin P., Higdon C., Rossi A. M., Emerson E., Finkelstein M., Floyd E., Harriman S., Atherton J., Hillerman S., Soderstrom C., Kou K., Gant T., Noe M. C., Foster B., Rastinejad F., Marx M. A., Schaeffer T., Whalen P. M., Roberts W. G. Pharmacological characterization of CP–547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy. Cancer Res. 2003; 63(21)7301–7309, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tolcher A. W., O'Leary J. J., DeBono J. S., Caulkins J. D., Molpus K., Sutula K., Ferrante K. J., Gualberto A., Noe D. A., Huberman M., Rowinsky E. K., Healey D. A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc. Am. Soc. Clin. Oncol. 2002, Abs. 334[CSA]
   PubMedGoogle Scholar
• Medinger M., Mross K., Zirrgiebel U., Strecker R., Wheeler C., Clack G., Lewis J., Puchalski T. A., Unger C., Drevs J. Phase I dose-escalation study of the highly potent VEGF receptor kinase inhibitor, AZD2171, in patients with advanced cancers with liver metastases. Proc. Am. Soc. Clin. Oncol., J. Clin. Oncol. 2004; 22(14S)3055, [CSA]
   Google Scholar
• Suttle A. B., Hurwitz H., Dowlati A., Fernando N., Savage S., Coviello K., Dar M., Ertel P., Whitehead B., Pandite L. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S)3054, [CSA]
   Google Scholar
• Pavco P. A., Bouhana K. S., Gallegos A. M., Agrawal A., Blanchard K. S., Grimm S. L., Jensen K. L., Andrews L. E., Wincott F. E., Pitot P. A., Tressler R. J., Cushman C., Reynolds M. A., Parry T. J. Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin. Cancer. Res. 2000; 6(5)2094–2103, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Weng D. E., Weiss P., Kellackey C., Ganapathi R., Parker V. P., Usman N., Cowens J. W., Smith J. A., Jackson T. E., Radka S. F., DiFrancesco A., Kim J. A., Borden E. C. Angiozyme Pharmacokinetic and Safety Results: a Phase I/II Study in Patients with Refractory Solid Tumors. Proc. Am. Soc. Clin. Oncol. 2001, Abs. 393[CSA]
   Google Scholar
• Venook A., Hurwitz H., Cunningham C., Burris H. A., Aitchison R., Radka S., Pavco P., Capra W., Wolin M., Usman N. Relationship of clinical outcome in metastatic colorectal carcinoma to levels of soluble VEGFR-1: Results of a phase II trial of a ribozyme targeting the pre-mRNA of VEGFR-1 (angiozyme), in combination with chemotherapy. Proc. Am. Soc. Clin. Oncol. 2003, Abs. 1025[CSA]
   Google Scholar
• Saltz L. B., Cox J. V., Blanke C., Rosen L. S., Fehrenbacher L., Moore M. J., Maroun J. A., Ackland S. P., Locker P. K., Pirotta N., Elfring G. L., Miller L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 2000; 343(13)905–914, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Masood R., Cai J., Zheng T., Smith D. L., Hinton D. R., Gill P. S. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001; 98(6)1904–1913, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Levine A. M., Quinn D. I., Gorospe G., Lenz H. J., Tulpule A. Phase I trial of anti-sense oligonucleotide vascular endothelial growth factor (VEGF-AS, Veglin) in patients with relapsed and refractory malignancies. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S)3008, [CSA]
   Google Scholar
• Imdahl A., Bognar G., Schulte-Monting J., Schoffel U., Farthmann E. H., Ihling C. Predictive factors for response to neoadjuvant therapy in patients with oesophageal cancer. Eur. J. Cardiothorac. Surg. 2002; 21(4)657–663, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Inoue K., Ozeki Y., Suganuma T., Sugiura Y., Tanaka S. Vascular endothelial growth factor expression in primary esophageal squamous cell carcinoma. Association with angiogenesis and tumor progression. Cancer 1997; 79(2)206–213, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Uchida S., Shimada Y., Watanabe G., Tanaka H., Shibagaki I., Miyahara T., Ishigami S., Imamura M. In oesophageal squamous cell carcinoma vascular endothelial growth factor is associated with p53 mutation, advanced stage and poor prognosis. Br. J. Cancer 1998; 77(10)1704–1709, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Auvinen M. I., Sihvo E. I., Ruohtula T., Salminen J. T., Koivistoinen A., Siivola P., Ronnholm R., Ramo J. O., Bergman M., Salo J. A. Incipient angiogenesis in Barrett's epithelium and lymphangiogenesis in Barrett's adenocarcinoma. J. Clin. Oncol. 2002; 20(13)2971–2979, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lord R. V., Park J. M., Wickramasinghe K., DeMeester S. R., Oberg S., Salonga D., Singer J., Peters J. H., Danenberg K. D., Demeester T. R., Danenberg P. V. Vascular endothelial growth factor and basic fibroblast growth factor expression in esophageal adenocarcinoma and Barrett esophagus. J. Thorac. Cardiovasc. Surg. 2003; 125(2)246–253, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mobius C., Stein H. J., Becker I., Feith M., Theisen J., Gais P., Jutting U., Siewert J. R. The ‘angiogenic switch’ in the progression from Barrett's metaplasia to esophageal adenocarcinoma. Eur. J. Surg. Oncol. 2003; 29(10)890–894, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Couvelard A., Paraf F., Gratio V., Scoazec J. Y., Henin D., Degott C., Flejou J. F. Angiogenesis in the neoplastic sequence of Barrett's oesophagus. Correlation with VEGF expression. J. Pathol. 2000; 192(1)14–18, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Mobius C., Stein H. J., Becker I., Feith M., Theisen J., Gais P., Jutting U., Siewert J. R. Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma. World. J. Surg. 2004; 28(7)675–679, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Torres C., Wang H., Turner J., Shahsafaei A., Odze R. D. Prognostic significance and effect of chemoradiotherapy on microvessel density (angiogenesis) in esophageal Barrett's esophagus-associated adenocarcinoma and squamous cell carcinoma. Hum. Pathol. 1999; 30(7)753–758, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Amioka T., Kitadai Y., Tanaka S., Haruma K., Yoshihara M., Yasui W., Chayama K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer. 2002; 38(10)1413–1419, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ichikura T., Tomimatsu S., Ohkura E., Mochizuki H. Prognostic significance of the expression of vascular endothelial growth factor (VEGF) and VEGF-C in gastric carcinoma. J. Surg. Oncol. 2001; 78(2)132–137, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ishikawa M., Kitayama J., Kazama S., Nagawa H. Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn. J. Clin. Oncol. 2003; 33(1)21–27, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kakeji Y., Koga T., Sumiyoshi Y., Shibahara K., Oda S., Maehara Y., Sugimachi K. Clinical significance of vascular endothelial growth factor expression in gastric cancer. J. Exp. Clin. Cancer Res. 2002; 21(1)125–129, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tamburini A., Tomajer V., Gregorc V., Albarello L., Di Palo S., Arrigoni G., Villa E., Staudacher C. Role of VEGF-A, VEGF-D, COX-2 as prognostic factors in curatively resected gastric cancer. in Gastrointestinal Cancers Symposium, San Francisco, CA 2004, Am. Soc. Clin. Oncol
   Google Scholar
• Yan C., Zhu Z. G., Yu Y. Y., Ji J., Zhang Y., Ji Y. B., Yan M., Chen J., Liu B. Y., Yin H. R., Lin Y. Z. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J Gastroenterol. 2004; 10(6)783–790, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Duff S. E., Li C., Jeziorska M., Kumar S., Saunders M. P., Sherlock D., O'Dwyer S. T., Jayson G. C. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br. J. Cancer. 2003; 89(3)426–430, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Leung W. K., To K. F., Go M. Y., Chan K. K., Chan F. K., Ng E. K., Chung S. C., Sung J. J. Cyclooxygenase-2 upregulates vascular endothelial growth factor expression and angiogenesis in human gastric carcinoma. Int. J. Oncol. 2003; 23(5)1317–1322, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Shi H., Xu J. M., Hu N. Z., Xie H. J. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World. J. Gastroenterol. 2003; 9(7)1421–1426, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Kamiya K., Konno H., Tanaka T., Baba M., Matsumoto K., Sakaguchi T., Yukita A., Asano M., Suzuki H., Arai T., Nakamura S. Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn. J. Cancer Res. 1999; 90(7)794–800, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Matsumoto K., Konno H., Tanaka T., Baba M., Kanai T., Kamiya K., Ohba K., Nakamura S. Combination therapy with vascular endothelial growth factor neutralizing antibody and mitomycin C on human gastric cancer xenograft. Jpn. J. Cancer Res. 2000; 91(7)748–752, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Warshaw A. L., Fernandez-del Castillo, Pancreatic C. carcinoma. N. Engl. J. Med. 1992; 326(7)455–465, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Itakura J., Ishiwata T., Friess H., Fujii H., Matsumoto Y., Buchler M. W., Korc M. Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin. Cancer Res. 1997; 3(8)1309–1316, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Niedergethmann M., Hildenbrand R., Wostbrock B., Hartel M., Sturm J. W., Richter A., Post S. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25(2)122–129, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Fujimoto K., Hosotani R., Wada M., Lee J. U., Koshiba T., Miyamoto Y., Tsuji S., Nakajima S., Doi R., Imamura M. Expression of two angiogenic factors, vascular endothelial growth factor and platelet-derived endothelial cell growth factor in human pancreatic cancer, and its relationship to angiogenesis. Eur. J. Cancer 1998; 34(9)1439–1447, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Lim Y. J., Lee J. K., Park C. K., Song S. Y., Jang W. Y., Ha H. Y., Park D. I., Lee K. T., Paik S. W., Yoo B. C., Rhee J. C. Prognostic value of VEGF in human pancreatic ductal adenocarcinoma. Korean. J. Intern. Med. 2004; 19(1)10–14, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Ebert M., Yokoyama M., Friess H., Kobrin M. S., Buchler M. W., Korc M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int. J. Cancer 1995; 62(5)529–535, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Fujioka S., Yoshida K., Yanagisawa S., Kawakami M., Aoki T., Yamazaki Y. Angiogenesis in pancreatic carcinoma: thymidine phosphorylase expression in stromal cells and intratumoral microvessel density as independent predictors of overall and relapse-free survival. Cancer 2001; 92(7)1788–1797, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ohta T., Yamamoto M., Numata M., Iseki S., Tsukioka Y., Miyashita T., Kayahara M., Nagakawa T., Miyazaki I., Nishikawa K., Yoshitake Y. Expression of basic fibroblast growth factor and its receptor in human pancreatic carcinomas. Br. J. Cancer 1995; 72(4)824–831, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bockhorn M., Tsuzuki Y., Xu L., Frilling A., Broelsch C. E., Fukumura D. Differential vascular and transcriptional responses to anti-vascular endothelial growth factor antibody in orthotopic human pancreatic cancer xenografts. Clin. Cancer Res. 2003; 9(11)4221–4226, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bruns C. J., Shrader M., Harbison M. T., Portera C., Solorzano C. C., Jauch K. W., Hicklin D. J., Radinsky R., Ellis L. M. Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing orthotopically in nude mice. Int. J. Cancer 2002; 102(2)101–108, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Baker C. H., Solorzano C. C., Fidler I. J. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res. 2002; 62(7)1996–2003, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Crane C. H., Ellis L. M., Xiong H., Ho L., O'Reilly M., Evans D. B., Delclos M. E., Abbruzzese J. L., Charnsangavej C., Ng C., Tamm E. P., Wolff R. A. Preliminary results of a phase I study of rhuMab VEGF (bevacizumab) with concurrent radiotherapy (XRT) and capecitabine (CAP). in Gastrointestinal Cancers Symposium, San Francisco, CA 2004, Am. Soc. Clin. Oncol
   Google Scholar
• Kindler H. L., Friberg G., Stadler W. M., Singh D. A., Locker G., Nattam S., Kozloff M., Kasza K., Vokes E. E. Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S)4009, [CSA]
   Google Scholar
• Burris H. A., 3rd, Moore M. J., Andersen J., Green M. R., Rothenberg M. L., Modiano M. R., Cripps M. C., Portenoy R. K., Storniolo A. M., Tarassoff P., Nelson R., Dorr F. A., Stephens C. D., Von Hoff D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15(6)2403–2413, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Honda H., Tajima T., Taguchi K., Kuroiwa T., Yoshimitsu K., Irie H., Aibe H., Shinozaki K., Asayama Y., Shimada M., Masuda K. Recent developments in imaging diagnostics for HCC: CT arteriography and CT arterioportography evaluation of vascular changes in premalignant and malignant hepatic nodules. J. Hepatobiliary Pancreat. Surg. 2000; 7(3)245–251, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Poon R. T., Ho J. W., Tong C. S., Lau C., Ng I. O., Fan S. T. Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br. J. Surg. 2004; 91(10)1354–1360, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Zhao J., Hu J., Cai J., Yang X., Yang Z. Vascular endothelial growth factor expression in serum of patients with hepatocellular carcinoma. Chin. Med. J. (Engl.) 2003; 116(5)772–776, [CSA]
   PubMed Web of Science ®Google Scholar
• Hirohashi K., Yamamoto T., Uenishi T., Ogawa M., Sakabe K., Takemura S., Shuto T., Tanaka H., Kubo S., Kinoshita H. CD44 and VEGF expression in extrahepatic metastasis of human hepatocellular carcinoma. Hepatogastroenterology 2004; 51(58)1121–1123, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jeng K. S., Sheen I. S., Wang Y. C., Gu S. L., Chu C. M., Shih S. C., Wang P. C., Chang W. H., Wang H. Y. Is the vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma of prognostic value after resection?. World J. Gastroenterol. 2004; 10(5)676–681, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Jeng K. S., Sheen I. S., Wang Y. C., Gu S. L., Chu C. M., Shih S. C., Wang P. C., Chang W. H., Wang H. Y. Prognostic significance of preoperative circulating vascular endothelial growth factor messenger RNA expression in resectable hepatocellular carcinoma: a prospective study. World J Gastroenterol. 2004; 10(5)643–648, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Tanaka S., Mori M., Sakamoto Y., Makuuchi M., Sugimachi K., Wands J. R. Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J. Clin. Invest. 1999; 103(3)341–345, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Schwartz J. D., Schwartz M., Goldman J., Lehrer D., Coll D., Kinkabwala M., Wadler S. Bevacizumab in hepatocellular carcinoma in patients without metastasis and without invasion of the portal vein. Proc. Am. Soc. Clin. Oncol., Clin J. Oncol. 2004; 22(14S)4088, [CSA]
   Google Scholar
• Zhu A. X., Sahani D., Norden-Zfoni A., Holalkere N. S., Blaszkowsky L., Ryan D. P., Clark J. W., Taylor K., Heymach J. V., Stuart K. A Phase II Study of Gemcitabine, Oxaliplatin in Combination with Bevacizumab (GEMOX-B) in Patients with Hepatocellular Carcinoma. in Proc. Am. Soc. Clin. Oncol., Orlando, FL 2005, Abs. 134
   Google Scholar
• Terris B., Scoazec J. Y., Rubbia L., Bregeaud L., Pepper M. S., Ruszniewski P., Belghiti J., Flejou J., Degott C. Expression of vascular endothelial growth factor in digestive neuroendocrine tumours. Histopathology 1998; 32(2)133–138, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Konno H., Arai T., Tanaka T., Baba M., Matsumoto K., Kanai T., Nakamura S., Baba S., Naito Y., Sugimura H., Yukita A., Asano M., Suzuki H. Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn. J. Cancer Res. 1998; 89(9)933–939, [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yao J. C., Ng C., Hoff P. M., Phan A. T., Hess K., Chen H., Wang X., Abbruzzese J. L., Ajani J. A. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. in Proc. Am. Soc. Clin. Oncol., Orlando, FL 2005, Abs. 4007
   Google Scholar
• Kulke M., Lenz H. J., Meropol N. J., Posey J., Ryan D. P., Picus J., Bergsland E., Stuart K., Baum C. M., Fuchs C. S. A phase 2 study to evaluate the efficacy and safety of SU11248 in patients (pts) with unresectable neuroendocrine tumors (NETs). in Proc. Am. Soc. Clin. Oncol., Orlando, FL 2005, Abs. 4008
   Google Scholar
• Miettinen M., Lasota J. Gastrointestinal stromal tumors–definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438(1)1–12, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Demetri G. D., von Mehren M., Blanke C. D., Van den Abbeele A. D., Eisenberg B., Roberts P. J., Heinrich M. C., Tuveson D. A., Singer S., Janicek M., Fletcher J. A., Silverman S. G., Silberman S. L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B. J., Corless C., Fletcher C. D., Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 2002; 347(7)472–480, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar